The 79 references in paper S. Avdeev N., С. Авдеев Н. (2017) “Легочная гипертензия при саркоидозе // Pulmonary hypertension in sarcoidosis” / spz:neicon:pulmonology:y:2016:i:6:p:725-735

1
Simonneau G., Gatzoulis M.A., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.2013; 62: D34–41.
(check this in PDF content)
2
Cordova F.C., D'Alonzo G. Sarcoidosis-associated pulmonary hypertension. Curr. Opin. Pulm. Med.2013; 19: 531–537.
(check this in PDF content)
3
Battesti J.P., Georges R., Basset F., Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax. 1978; 33: 76–84.
(check this in PDF content)
4
Głuskowski J., Hawryłkiewicz I., Zych D. et al. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration. 1984; 46: 26–32.
(check this in PDF content)
5
Handa T., Nagai S., Miki S. et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006; 129: 1246–1252.
(check this in PDF content)
6
Milman N., Burton C.M., Iversen M. et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J. Heart Lung Transplant. 2008; 27: 329–334.
(check this in PDF content)
7
Mitchell D.N., Scadding J.G. Sarcoidosis.Am. Rev. Respir. Dis.1974; 110 (6): 774–802.
(check this in PDF content)
8
Rizzato G., Pezzano A., Sala G. et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur. J. Respir. Dis.1983; 64: 121–128.
(check this in PDF content)
9
Shorr A.F., Davies D.B., Nathan S.D. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest. 2002; 122: 233–238.
(check this in PDF content)
10
Sulica R., Teirstein A.S., Kakarla S. et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005; 128: 1483–1489.
(check this in PDF content)
11
Nunes H., Humbert M., Capron F. et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006; 61: 68–74
(check this in PDF content)
12
Shah L. Lung transplantation in sarcoidosis. Semin. Respir. Crit. Care Med.2007; 28: 134–140.
(check this in PDF content)
13
Bourbonnais J.M., Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur. Respir. J. 2008; 32: 296–302.
(check this in PDF content)
14
Maimon N., Salz L., Shershevsky Y. et al. D. Sarcoidosisassociated pulmonary hypertension in patients with nearnormal lung function. Int. J. Tuberc. Lung Dis.2013; 17: 406–411.
(check this in PDF content)
15
Arcasoy S.M., Christie J.D., Pochettino A. et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001; 120: 873–880.
(check this in PDF content)
16
Shorr A.F., Helman D.L., Davies D.B., Nathan S.D. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur. Respir. J.2005; 25: 783–788.
(check this in PDF content)
17
GalièN., Hoeper M.M., Humbert M. et al.Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J.2009; 30: 2493–2537.
(check this in PDF content)
18
Lahm T., Chakinala M.M. World Health Organization group 5 pulmonary hypertension.Clin. Chest Med.2013; 34: 753–778.
(check this in PDF content)
19
Preston I.R., Klinger J.R., Landzberg M.J. et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest. 2001; 120: 866–872.
(check this in PDF content)
20
Takemura T., Matsui Y., Oritsu M. et al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows. Arch. Pathol. Anat. Histopathol. 1991; 418: 361–368.
(check this in PDF content)
21
Takemura T., Matsui Y., Saiki S., Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum. Pathol. 1992; 23: 1216–1223.
(check this in PDF content)
22
Rosen Y., Moon S., Huang C.T. et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch. Pathol. Lab. Med.1977; 101: 170–174.
(check this in PDF content)
23
Carrington C.B. Structure and function in sarcoidosis. Ann. NY Acad. Sci. 1976; 278: 265–283.
(check this in PDF content)
24
Rosen Y. Pathology of sarcoidosis. Semin. Respir. Crit. Care Med. 2007; 28 (1): 36–52.
(check this in PDF content)
25
Shorr A.F., Davies D.B., Nathan S.D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003; 124: 922–928.
(check this in PDF content)
26
Damuth T.E., Bower J.S., Cho K., Dantzker D.R. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest. 1980; 78: 888–891.
(check this in PDF content)
27
Gaston B., Drazen J.M., Loscalzo J., Stamler J.S. The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med.1994; 149: 538–551.
(check this in PDF content)
28
Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.1995; 333: 214–221.
(check this in PDF content)
29
Milman N., Svendsen C.B., Iversen M. et al. Sarcoidosisassociated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil.Clin. Respir. J.2009; 3: 207–213.
(check this in PDF content)
30
GalièN., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension.Cardiovasc. Res. 2004; 61: 227–237.
(check this in PDF content)
31
Giaid A., Yanagisawa M., Langleben D. et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1993; 328: 1732–1739.
(check this in PDF content)
32
Sofia M., Mormile M., Faraone S. et al. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis. 1995; 12: 118–123. Авдеев С.Н.Легочная гипертензия при саркоидозе
(check this in PDF content)
33
Reichenberger F., Schauer J., Kellner K. et al. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung. 2001; 179: 163–174.
(check this in PDF content)
34
Terashita K., Kato S., Sata M. et al. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology. 2006; 11: 145–151.
(check this in PDF content)
35
Letizia C., Danese A., Reale M.G. et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva. Med. 2001; 43: 257–261.
(check this in PDF content)
36
Barnett C.F., Bonura E.J., Nathan S.D. et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest. 2009; 135: 1455–1461.
(check this in PDF content)
37
Baughman R.P., Engel P.J., Meyer C.A. et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis.2006; 23: 108–116.
(check this in PDF content)
38
Foley R.J., Metersky M.L. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration. 2008; 75: 211–214.
(check this in PDF content)
39
Hoffstein V., Ranganathan N., Mullen J.B. Sarcoidosis simulating pulmonary veno-occlusive disease. Am. Rev. Respir. Dis.1986; 134: 809–811.
(check this in PDF content)
40
Jones R.M., Dawson A., Jenkins G.H. et al. Sarcoidosisrelated pulmonary veno-occlusive disease presenting with recurrent haemoptysis.Eur. Respir. J.2009; 34: 517–520.
(check this in PDF content)
41
Portier F., Lerebours-Pigeonniere G., Thiberville L. et al. Sarcoidosis simulating a pulmonary veno-occlusive disease. Rev. Mal. Respir. 1991; 8: 101–102.
(check this in PDF content)
42
Wagenvoort C.A., Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows. Arch. Pathol. Anat. Histol.1974; 364: 69–79.
(check this in PDF content)
43
Montani D., O'Callaghan D.S., Savale L. et al. Pulmonary veno-occlusive disease: recent progress and current challenges.Respir. Med.2010; 104 (Suppl. 1): S23–S32.
(check this in PDF content)
44
Roberts W.C., McAllister H.A. Jr, Ferrans V.J. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am. J. Med.1977; 63: 86–108.
(check this in PDF content)
45
Mehta D., Lubitz S.A., Frankel Z. et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008; 133: 1426–1435.
(check this in PDF content)
46
Perry A., Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch. Pathol. Lab. Med. 1995; 119: 167–172.
(check this in PDF content)
47
Iwai K., Sekiguti M., Hosoda Y. et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994; 11: 26–31.
(check this in PDF content)
48
Saggar R., Saggar R., Aboulhosn J. et al. Diagnosis and hemodynamic assessment of pulmonary arterial hypertension. Semin. Respir. Crit. Care Med. 2009; 30: 399–410.
(check this in PDF content)
49
Hoeper M.M., Lee S.H., Voswinckel R. et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers.J. Am. Coll. Cardiol. 2006; 48: 2546–2552.
(check this in PDF content)
50
Arcasoy S.M., Christie J.D., Ferrari V.A. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med. 2003; 167: 735–740.
(check this in PDF content)
51
Nathan S.D., Shlobin O.A., Barnett S.D. et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis.Respir. Med. 2008; 102: 1305–1310.
(check this in PDF content)
52
Zisman D.A., Ross D.J., Belperio J.A. et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir. Med. 2007; 101: 2153–2159.
(check this in PDF content)
53
Rich J.D., Shah S.J., Swamy R.S. et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest. 2011; 139: 988–993.
(check this in PDF content)
54
Devaraj A., Wells A.U., Meister M.G. et al. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology. 2008; 249: 1042–1049.
(check this in PDF content)
55
Shino M.Y., Lynch J.P., Fishbein M.C. Sarcoidosis-associated pulmonary hypertension and lung transplantation for sarcoidosis.Semin. Respir. Crit. Care Med. 2014; 35: 362–371.
(check this in PDF content)
56
Emirgil C., Sobol B.J., Herbert W.H., Trout K. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest. 1971; 60: 371–378.
(check this in PDF content)
57
Handa T., Nagai S., Ueda S. et al. Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis.Sarcoidosis Vasc. Diffuse Lung Dis. 2010; 27: 27–35.
(check this in PDF content)
58
Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis. N. Engl. J. Med.2007; 357: 2153–2165.
(check this in PDF content)
59
Lynch J.P. III, Kazerooni E.A., Gay S.E. Pulmonary sarcoidosis. Clin. Chest Med. 1997; 18: 755–785.
(check this in PDF content)
60
Macfarlane J.T. Prognosis in sarcoidosis. Br. Med. J. (Clin. Res. Ed.) 1984; 288: 1557–1558.
(check this in PDF content)
61
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.Am. J. Respir. Crit. Care Med. 1999; 160: 736–755.
(check this in PDF content)
62
Baughman R.P. Pulmonary sarcoidosis. Clin. Chest Med. 2004; 25: 521–530.
(check this in PDF content)
63
Patterson K.C., Strek M.E. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes.Ann. Am. Thorac. Soc. 2013; 10: 362–370.
(check this in PDF content)
64
Lynch J.P. III, Ma Y.L., Koss M.N., White E.S. Pulmonary sarcoidosis. Semin. Respir. Crit. Care Med. 2007; 28: 53–74.
(check this in PDF content)
65
Gluskowski J., Hawrylkiewicz I., Zych D., Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur. Respir. J.1990; 3: 403–407.
(check this in PDF content)
66
Pitsiou G., Papakosta D., Bouros D. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration. 2011; 82: 294–304.
(check this in PDF content)
67
Patel N.M., Lederer D.J., Borczuk A.C., Kawut S.M. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007; 132: 998–1006.
(check this in PDF content)
68
Fisher K.A., Serlin D.M., Wilson K.C. et al. Sarcoidosisassociated pulmonary hypertension: outcome with longterm epoprostenol treatment. Chest. 2006; 130: 1481–1488.
(check this in PDF content)
69
Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.Am. J. Respir. Crit. Care Med. 1999; 160: 600–607.
(check this in PDF content)
70
Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur. Respir. Rev.2009; 18: 29–34.
(check this in PDF content)
71
Baughman R.P., Judson M.A., Lower E.E. et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc. Diffuse Lung Dis.2009; 26: 110–120.
(check this in PDF content)
72
Baughman R.P. Pulmonary hypertension associated with sarcoidosis.Arthritis Res. Ther. 2007; 9 (Suppl. 2): S8.
(check this in PDF content)
73
Sharma S., Kashour T., Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex. Heart Inst. J.2005; 32: 405–410.
(check this in PDF content)
74
Baughman R.P., Culver D.A., Cordova F.C. et al. Bosentan for sarcoidosis associated pulmonary hypertension: A double-blind placebo controlled randomized trial. Chest. 2014; 145: 810–817.
(check this in PDF content)
75
Dobarro D., Schreiber B.E., Handler C. et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and metaanalysis of the published data.Am. J. Cardiol. 2013; 111: 278–285.
(check this in PDF content)
76
Barnett C.F., Bonura E.J., Nathan S.D. et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest. 2009; 135: 1455–1461.
(check this in PDF content)
77
Baughman R.P., Engel P.J., Meyer C.A. et al. Pulmonary hypertension in sarcoidosis.Sarcoidosis Vasc. Diffuse Lung Dis. 2006; 23: 108–116.
(check this in PDF content)
78
Foley R.J., Metersky M.L. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration. 2008; 75: 211–214.
(check this in PDF content)
79
Judson M.A., Highland K.B., Kwon S. et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc. Diffuse Lung Dis. 2011; 28: 139–145. Поступила 05.07.16 Received July 05, 2016
(check this in PDF content)